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ejection fraction changed in a negative direction in patients of
ADHF who are troponin positive.
Though from the present study, we got some positive directions
in making prognostic correlation of ADHF patients with troponin
positivity, further large prospective randomized trials are neces-
sary before coming to definite conclusion in making recommen-
dation for doing quantitative troponin T in all patients of acute
decompensated heart failure for prognosis and guiding therapy.
Post renal transplantation e Effect on ventricular
dysfunction and pulmonary hypertension
Gandhamdara Kiran Kumar
Narayana Medical College and Hospital, Nellore, India
Background: Heart disease is a frequent complication of chronic
kidney disease and the major cause of death in patients on renal
replacement therapy. The purpose of this study was to evaluate
the impact of successful renal transplantation on systolic and
diastolicventricular dysfunction and pulmonary arterial hyper-
tension in patients with chronic kidney disease (CKD).
Methods: The study included 35 patients >18 years of age with
CKD who had successful kidney transplantations. Ventricular
function and pulmonary arterial pressure were evaluated by
echocardiography before and 1 year after transplant.
Results: The mean age of subjects was 40 _+ 14 years, and 63%
were men. Mean left ventricular ejection fraction (LVEF) was 52 +_
16%. Before transplant, 28 (80%) of the patients had ventricular
dysfunction (34.3% diastolic and 45.7% systolic). Pulmonary arte-
rial hypertension was found in 48.6%. Ventricular dysfunction
was associated with dialysis of >2 years duration before trans-
plant. The LVEF of the entire group increased from 52% to 64% (P <
.001) by 12 months after kidney transplant. Left ventricular di-
ameters, wall thickness, and pulmonary arterial systolic pressure
decreased significantly after transplantation Echocardiograms
became normal 1 year after transplant in 8 (66.7%) of the patients
with diastolic dysfunction and 9 (56.2%) with systolic dysfunction,
and diastolic dysfunction persisted in 5 (31.2%).
Conclusions: Renal transplantation has led to considerable
improvement in left ventricular systolic and diastolic function as
well as pulmonary arterial pressure of patients with CKD, optimal
treatment for dysfunction and transplant as soon as possible is
recommended.
Echocardiographic parameters and cardiac failure
in end-stage renal disease on vigorous
hemodialysis
Gandhamdara Kiran Kumar, Ashutosh Kumar
Narayana Medical College and Hospital, Nellore, India
Background: Abnormal Echocardiographic parameters are seen in
all patients starting dialysis therapy and are associated with the
development of cardiac failure and death.
Objective: to know whether regression of cardiac abnormalities is
associated with an improvement in prognosis with vigorous renal
dialysis.
Methods: As part of a prospective cohort study with mean follow-
up of 6 mo, 57 patients had echocardiography at inception and
after 1 week of vigorous renal dialysis therapy.
Results: Improvements in left ventricular (LV)mass index, volume
index, and fractional shortening were seen in 48, 48, and 46%,
respectively. Twenty-four patients had developed cardiac failure
by 6 months of dialysis therapy. Twenty-six percent of the
remaining 27 patients subsequently developed new-onset cardiac
failure. The mean changes in LV mass index were 17 g/m(2) in
those who subsequently developed cardiac failure compared with
0 g/m(2) among those who did not (P ¼ 0.05). The corresponding
values were -8 versus 0% for fractional shortening (P < 0.0001).
Conclusion: Regression of LV abnormalities is associated with an
improved cardiac outcome in endstage renal disease patients on
vigorous dialysis.
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Background: There are no contemporary data on etiologies,
management and outcomes of heart failure in India. To determine
etiologies andmanagement of heart failure in hospital- and clinic-
based patients in India we performed a study.
Methods: Successive patients presenting to a tertiary care non-
government hospital with acute decompensated heart failure
(ADHF, n¼102) and stable heart failure (SHF, n¼179) were enrolled.
Both the groups were followed for 90 days. Etiology of heart failure
was diagnosed using clinical examination and echocardiography.
Details of in-hospital, discharge and 90-day medications were
obtained in both groups. Outcomes (mortality) data were recor-
ded. Descriptive statistics are reported.
Results: Prevalence of various cardiovascular diseases in ADHF vs
SHF patients, respectively, was coronary heart disease 50.0 vs
53.6%, hypertension 60.8 vs 44.7%, cardiomyopathy 16.7vs 7.3%,
rheumatic heart disease 4.9 vs 14.0%, and hypertrophic cardio-
myopathy 1.0 vs 7.3%. Heart failure with normal ejection fraction
was in 23 ADHF and 2 SHF patients. In-hospital treatments
included diuretics, nitrates, angiotensin converting enzyme (ACE)
inhibitors, digoxin, anticoagulants and vasopressors. At discharge
significantly greater number of patients with ADHF vs SHF were
on loop-diuretics (95.5 vs 78.2%), anti-platelets (74.4 vs 64.2%) and
anti-arrhythmics (23.3 vs 6.1%) while lesser were on thiazides (1.5
vs 9.5%), anti-aldosterone (33.4 vs 43.0%), ACE inhibitors (30.0 vs
35.2%), angiotensin receptor blockers (ARBs, 4.5 vs 40.8%) and
beta-blockers (33.4 vs 45.8%) (p<0.05). Use of digoxin {28.9 vs
31.8%), nitrates (32.2 vs 30.7%) and anticoagulants (11.1 vs 8.9%)
was similar. At 90 days, in ADHF vs SHF patients lower use of ACE
inhibitors (42.4 vs00.0%) and ARBs (4.5 vs. 0.0%) and similar use of
beta-blockers (48.5 vs00.0%) was observed. In ADHF patients, in-
hospital mortality was 10.3% (n¼11). Cumulative 90-day mortality
in ADHF was 45.0% (n¼46) while in SHF patients was 1.1% (n¼7)
(p<0.05).
Conclusions: This study shows that coronary and hypertensive
heart diseases are important causes of heart failure at a tertiary-
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care hospital in India. Rheumatic heart disease and primary
cardiomyopathies are also present in significant proportion. In
ADHF patients there is low use of evidence-based therapies
(ACE inhibitors/ARBs, beta-blockers) and short-term mortality is
high.
Hypertension
Evaluation and assessment of rosuvastatin 40 mg
treatment in high risk dyslipidemic patients
(EARTH Study)
R. Karnik, A. Trailokya, P. Kamlesh, Q. Mukaddam, M. Naik
Medical Services Division, Abbott Healthcare Private Limited, Mumbai,
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Background: Rosuvastatin is commonly used in the treatment of
dyslipidemia, however, studies with rosuvastatin 40 mg in Indian
patients with high cardiovascular risk are lacking.
Objective: To assess the safety and efficacy of rosuvastatin 40mg
in dyslipidemic patients with high cardiovascular risk.
Methods: In an open label, non-comparative, multicentric, post
marketing observational study, 574 Indian patients were
enrolled. Treatment was started with rosuvastatin 40 mg once
daily for one month. After one month, patients achieving target
goal of LDL-C < 70 mg/dl were shifted to rosuvastatin 20 mg once
daily for next two months and those not achieving were
continued on 40mg. At third month, patients achieving LDL-C <
70 mg/dl continued 20 mg and those not achieving the target goal
were continued on 40mg for next three months. Lipid profile was
repeated after six month. The primary evaluation parameter was
percentage of patients achieving target serum LDL-C goal < 70
mg/dl at the end of one, three and six month. The secondary
evaluation parameters included percentage reduction in serum
LDL-C, serum. total cholesterol, serum triglyceride and percent-
age increase in S. HDL-C level at the end of one, three and six
month, and effect on serum creatinine at six months. Global
assessment for efficacy and tolerability was recorded by the
doctor and patient at the end of six months. All adverse events
were also recorded.
Results: Compared to baseline, there was significant increase in
number of patients achieving serum LDL <70 mg/dl at one, three
and six months. Similarly, significant reduction in serum LDL,
total cholesterol and triglyceride level and increase in HDL was
seen at one, three and six months. There was no significant
effect on serum creatinine level. Most of the patients reported
efficacy as either excellent or good as evaluated by both doctors
and patients. Close to 95% of the patients reported tolerability as
“good” as per global evaluation of tolerability by patients as well
as doctors. Rosuvastatin was generally well tolerated. The
incidence of adverse event was 9.9% with headache, myalgia,
constipation and vomiting being the commonly reported
adverse events. All the adverse events were of mild to moderate
intensity and all of them resolved during the treatment. None of
the patient required termination of treatment because of
adverse event.
Conclusion: Rosuvastatin is effective and well tolerated medicine
for the treatment of dyslipidemic patients with high cardiovas-
cular risk.
Efficacy and safety of Telmisartan alone or in
combination with hydrochlorothiazide in patients
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Background: This study was conducted to evaluate the effect of
telmisartan or telmisartan with hydrochlorothiazide (HCTZ) with
or without patient’s education about the blood pressure (BP). This
education was focused on the reduction of body weight and
healthy life-style.
Methods: 922 patients of essential hypertension were included in
this study. The inclusion criteria were: essential hypertension
(BP140/90mmHg or BP130/80mmHg in diabetic patients), age >
18 year and treatment of hypertension with at least one of the
above anti-hypertensive drug. A total of 387 patients were treated
with telmisartan and 535 patients with telmisartan with HCTZ.
The randomization ratio for life style programme was 2:1. The life
style programme included a 30 mins structured interview and
written detailed materials focused on the healthy life style, diet
and weight reduction. Patients were followed up at 4 to 8 weeks
intervals.
Results: The decrease of BP (both systolic & diastolic) during tel-
misartan/telmisartan with HCTZ treatment was statistically
highly significant (P<0.001). The decrease of BP below 140/90
mmHg was attained in 78.55% patients treated with telmisartan
and in 66.64% patients treated with telmisartan with HCTZ. The
final BP values (both systolic and diastolic) of patients enrolled in
the life style programmewere not significant different from the BP
value in patients without the life style programme. The life-style
programme had more “normotensive” patients (73.41%) than the
patients not enrolled in the life style programme (69.70%). The
difference was not significant. The mean decrease of body weight
in the life-style programme patients was 2.64±4.11 kg, which was
significantly more than in the non-life style programme patients
(0.65±3.85 kg, p<0.05).
Conclusions: The telmisartan either alone or in combination with
hydrochlorothiazide is an effective and safe anti-hypertensive
drug. The educational programme led to the decrease of body
weight, but did not significantly change the BP values.
Efficacy and tolerance of cilnidipine in cases of
amlodipine e Induced edema in hypertensives
patients
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S S Hospital, IMS, Banaras Hindu University, Varanasi, India
Background: Ankle oedema is a common adverse effect of
Amlodipine, a widely used L-type Calcium Channel Blocker (CCB),
seen in about 15% of patients receiving the drug. Cilnidipine is a
newer third generation L/N-type CCB and is approved for the
treatment of essential hypertension. This study was, therefore,
planned to determine whether Cilnidipine therapy can produce
resolution of Amlodipine-induced oedema while maintaining
adequate control of blood pressure.
Methods: This study was carried out on 56 patients of essential
hypertension with Amlodipine-induced oedema. Concomitant
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